Imaging neuroinflammation in multiple sclerosis using TSPO-PET
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Conventional MR imaging (MRI) techniques form the cornerstone of multiple sclerosis (MS) diagnostics and clinical follow-up today. MRI is sensitive in demonstrating focal inflammatory lesions and diffuse atrophy. However, especially in progressive MS, there is increasingly widespread diffuse pathology also outside the plaques, often related to microglial activation and neurodegeneration. This cannot be detected using conventional MRI. Positron emission tomography (PET) imaging using 18-kDa translocator protein (TSPO) binding radioligands has recently shown promise as a tool to detect this diffuse pathology in vivo, and for the first time allows one to follow its development longitudinally. It is becoming evident that the more advanced the MS disease is, the more pronounced is microglial activation. PET imaging allows the detection of MS-related pathology at molecular level in vivo. It has potential to enable measurement of effects of new disease-modifying drugs aimed at reducing neurodegeneration and neuroinflammation. PET imaging could thus be included in the design of future clinical trials of progressive MS. There are still technical issues related to the quality of TSPO radioligands and post-processing methodology, and comparison of studies from different PET centres is challenging. In this review, we summarise the main evidence supporting the use of TSPO-PET as a tool to explore the diffuse inflammation in MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonrigid registration using free-form deformations: application to breast mr images
Rueckert, D., Sonoda, L. I., Hayes, C., Hill, D. L. G., Leach, M. O., & Hawkes, D. J. (1999) · IEEE Transactions on Medical Imaging · doi:10.1109/42.796284 · Cited by 5,265
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer, J. M., Bramow, S., Dal-Bianco, A., Lucchinetti, C. F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., & Lassmann, H. (2009) · Brain · doi:10.1093/brain/awp070 · Cited by 1,450
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200 · cited 1×
“binding in some studies of PD [26, 27] and AD [28, 29].”
BackgroundIn-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054
Progressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033 · cited 15×
“The WM lesions in RRMS are typically of the active-lesion type, and they are likely the pathologic correlate of clinical attacks [5].”
BackgroundInfluentialOwen, D. R., Yeo, A. J., Gunn, R. N., Song, K., Wadsworth, G., Lewis, A., Rhodes, C., Pulford, D. J., Bennacef, I., Parker, C. A., et al. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.147 · Cited by 779
A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis
Magliozzi, R., Howell, O. W., Reeves, C., Roncaroli, F., Nicholas, R., Serafini, B., Aloisi, F., & Reynolds, R. (2010) · Annals of Neurology · doi:10.1002/ana.22230 · Cited by 747
Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis
McMahon, E. J., Bailey, S. L., Castenada, C. V., Waldner, H., & Miller, S. D. (2005) · Nature Medicine · doi:10.1038/nm1202 · Cited by 694 · cited 8×
“This is considered a key event in maintaining the chronic inflammation in the CNS [12, 13].”
BackgroundInfluentialThe peripheral benzodiazepine binding site in the brain in multiple sclerosis
Banati, R. B., Newcombe, J., Gunn, R. N., Cagnin, A., Turkheimer, F., Heppner, F., Price, G., Wegner, F., Giovannoni, G., Miller, D. H., et al. (2000) · Brain · doi:10.1093/brain/123.11.2321 · Cited by 661
Edison, P., Archer, H. A., Gerhard, A., Hinz, R., Pavese, N., Turkheimer, F. E., Hammers, A., Tai, Y. F., Fox, N., Kennedy, A., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.08.001 · Cited by 513 · cited 1×
“binding in some studies of PD [26, 27] and AD [28, 29].”
BackgroundCosenza‐Nashat, M., Zhao, M. ‐., Suh, H. ‐., Morgan, J., Natividad, R., Morgello, S., & Lee, S. C. (2009) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.2008.01006.x · Cited by 459 · cited 3×
“This characteristic has been attributed to the ligand’s rather low penetration through the BBB [9], as well as to the ligand’s binding to structures in the brain vasculature, where endothelial and smooth muscle cells also express TSPO [35].”
BackgroundMRI in multiple sclerosis: current status and future prospects
Bakshi, R., Thompson, A. J., Rocca, M. A., Pelletier, D., Dousset, V., Barkhof, F., Inglese, M., Guttmann, C. R., Horsfield, M. A., & Filippi, M. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70137-6 · Cited by 348
Positron emission tomography and functional characterization of a complete PBR/TSPO knockout
Banati, R. B., Middleton, R. J., Chan, R., Hatty, C. R., Wai-Ying Kam, W., Quin, C., Graeber, M. B., Parmar, A., Zahra, D., Callaghan, P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6452 · Cited by 241 · cited 1×
“The use of [(11)C]PK11195 in clinical studies has been somewhat impeded due to its relatively low signal-to-noise ratio [39] despite of its high specificity for TSPO [40].”
Banati, R. B., Goerres, G. W., Myers, R., Gunn, R. N., Turkheimer, F. E., Kreutzberg, G. W., Brooks, D. J., Jones, T., & Duncan, J. S. (1999) · Neurology · doi:10.1212/wnl.53.9.2199 · Cited by 224
Kuhlmann, A. C., & Guilarte, T. R. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0741694.x · Cited by 215
Increased PK11195 PET binding in the cortex of patients with MS correlates with disability
Politis, M., Giannetti, P., Su, P., Turkheimer, F., Keihaninejad, S., Wu, K., Waldman, A., Malik, O., Matthews, P. M., Reynolds, R., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182635645 · Cited by 176
Rissanen, E., Tuisku, J., Rokka, J., Paavilainen, T., Parkkola, R., Rinne, J. O., & Airas, L. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.131698 · Cited by 171 · cited 3×
“[49] Cross sectional HC (8) SPMS (10) 49.”
BackgroundResultSelf-citationJi, B., Maeda, J., Sawada, M., Ono, M., Okauchi, T., Inaji, M., Zhang, M.-R., Suzuki, K., Ando, K., Staufenbiel, M., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2312-08.2008 · Cited by 169 · cited 1×
“Reactive astrocytes are also known to overexpress TSPO in response to injury [41] probably adding to the non-microglial specific binding [42, 43].”
BackgroundDickens, A. M., Vainio, S., Marjamäki, P., Johansson, J., Lehtiniemi, P., Rokka, J., Rinne, J., Solin, O., Haaparanta-Solin, M., Jones, P. A., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.125625 · Cited by 138 · cited 1×
“In addition, despite their better signal-to-noise ratio than [(11)C](R)PK11195, the second-generation TSPO ligands have also been shown to bind to reactive astrocytes [55, 56].”
BackgroundSelf-citationVersijpt, J., Debruyne, J. C., Van Laere, K. J., De Vos, F., Keppens, J., Strijckmans, K., Achten, E., Slegers, G., Dierckx, R. A., Korf, J., et al. (2005) · Multiple Sclerosis Journal · doi:10.1191/1352458505ms1140oa · Cited by 126 · cited 3×
“For instance, in some of the earlier studies using [(11)C]PK11195, cortical gray matter has been used as a reference region, whereas in others it was the main target of interest [48, 57, 59].”
BackgroundMethodResultRizzo, G., Veronese, M., Tonietto, M., Zanotti-Fregonara, P., Turkheimer, F. E., & Bertoldo, A. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.55 · Cited by 121 · cited 1×
“Importantly, attempts have been made to overcome this problem with novel kinetic modelling [70].”
BackgroundIn Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with18F-PBR111 PET
Colasanti, A., Guo, Q., Muhlert, N., Giannetti, P., Onega, M., Newbould, R. D., Ciccarelli, O., Rison, S., Thomas, C., Nicholas, R., et al. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.135129 · Cited by 100 · cited 1×
“In accordance with the results with [(11)C]PBR28, a study with [(18)F]PBR111 [67], where the subjects were matched according to their TSPO binding genotype, showed that the TSPO binding was increased in the T2 lesional and perilesional WM of RRMS patients (n = 11) when compared to healthy controls (n = 11), and the ra…”
ResultTomasi, G., Edison, P., Bertoldo, A., Roncaroli, F., Singh, P., Gerhard, A., Cobelli, C., Brooks, D. J., & Turkheimer, F. E. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.050583 · Cited by 97
Mechanism of microglia neuroprotection: Involvement of P2X 7,TNF α, and valproic acid
Masuch, A., Shieh, C., van Rooijen, N., van Calker, D., & Biber, K. (2016) · Glia · doi:10.1002/glia.22904 · Cited by 81
Cited by
In Vivo Imaging of Human Neuroinflammation
Albrecht, D. S., Granziera, C., Hooker, J. M., & Loggia, M. L. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00056 · Cited by 208
Owen, D. R., Narayan, N., Wells, L., Healy, L., Smyth, E., Rabiner, E. A., Galloway, D., Williams, J. B., Lehr, J., Mandhair, H., et al. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17710182 · Cited by 194
“Increases in the PET signal suggesting increased TSPO density generally have been interpreted in terms of increases in TSPO expression in microglia with activation.(42,48) However, under the assumptions Figure 3.”
BackgroundNatalizumab treatment reduces microglial activation in the white matter of the MS brain
Sucksdorff, M., Tuisku, J., Matilainen, M., Vuorimaa, A., Smith, S., Keitilä, J., Rokka, J., Parkkola, R., Nylund, M., Rinne, J., et al. (2019) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000574 · Cited by 71
Self-citationMisin, O., Matilainen, M., Nylund, M., Honkonen, E., Rissanen, E., Sucksdorff, M., & Airas, L. (2022) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001182 · Cited by 24
Self-citationKlyscz, P., Vigiser, I., Solorza Buenrostro, G., Motamedi, S., Leutloff, C. J., Schindler, P., Schmitz‐Hübsch, T., Paul, F., Zimmermann, H. G., & Oertel, F. C. (2025) · European Journal of Neurology · doi:10.1111/ene.70038 · Cited by 7
Metadata
- Authors
- Airas, L., Rissanen, E., & Rinne, J. O.
- Venue
- Clinical and Translational Imaging
- Published
- 2015-10-19
- Volume
- 3
- Issue
- 6
- Pages
- 461-473
- ISSN
- 2281-5872 (ISSN-L)
- 2281-7565
- OpenAlex
- W2132827246
- Cited by
- 70
- References
- 27
- FWCI
- 3.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.